22C3位点PD-L1与ki67 EGFR和血液指标相关性研究

doi:10.3969/j.issn.1006-6233.2021.02.012

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1217 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the relationship between the expression of programmed death receptor ligand-1(PD-L1) and the mutations of KI67 and EGFR in non-small-cell lung cancer. Methods: The expression of PD-L1(22C3)and Ki67 in 121 NSCLC tissues from November 2018 to July 2019 was detected with immunohistochemistry. The ARMS method was used to detect the mutations of the corresponding tissue EGFR gene, and the flow cytometry method was used to detect the proportion of serum CD3⁺, CD4⁺ and CD8⁺ T cells. The biochemical luminescence method was used to detect LDH, CEA, CA199 and CY211. The χ² analysis was used to analyze the differences in the distribution of PD-L1 expression in clinical factors, and the Spearman test was used to analyze the correlation between PD-L1 expression and EGFR gene, ki67 and blood indicators. Results: The low expression rate of PD-L1 was 38% (46/121), the high expression rate was 23.2% (28/121), the high expression rate of ki67 was 56.4% (57/101), and the EGFR mutation rate was 41.7% (20/48). The positive expression rate of PD-L1 in patients with stage III+IV and local lymph node metastasis was significantly higher than that in patients with I+II and without lymph node metastasis, and the difference was statistically significant (χ²=6.636, 7.726, P<0.05). The positive expression rate of PD-L1 was significantly correlated with EGFR mutants, high ki67 expression, increased number of CD8⁺ cells, and increased LDH, and was positively correlated (P<0.05). Conclusion: The expression rate of PD-L1 (22C3) is high in patients with lung cancer, and the expression rate of PD-L1 is significantly increased in patients with advanced staging, lymph node metastasis, high expression of ki67, EGFR mutation, CD8⁺ T cell number, and LDH. Related to clinical indicators with poor prognosis, it is an indicator for screening Pembrolizumab treatment and may also become a potential prognostic marker for NSCLC.

Key words： NSCLC PD-L1 EGFR Ki67

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2021.02.012 OR http://www.hbyxzzs.cn/EN/Y2021/V27/I2/233

[1] Chakravarti N,V G Prieto. Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs:immunohistochemistry analysis[J]. Transl Lung Cancer Res,2015,4(6):743~751.
[2] Zhou G W,Y Xiong S. Chen,et al. Anti-PD-1/PD-L1 antibody therapy for pretreated advanced nonsmall-cell lung cancer:A meta-analysis of randomized clinical trials[J]. Medicine (Baltimore),2016,95(35):e4611.
[3] Zak K M ,R Kitel S, Przetocka,et al. Structure of the complex of human programmed death 1,PD-1,and its ligand PD-L1[J]. Structure,2015,23(12):2341~2348.
[4] Lin C,X Chen,M Li,et al. Programmed death-ligand 1 expression predicts tyrosine kinase inhibitor response and better prognosis in a cohort of patients with epidermal growth factor receptor mutation-positive lung adenocarcinoma[J]. Clin Lung Cancer,2015,16(5):e25~e35.
[5] Koh J, H Go,B Keam,et al. Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma:comparison with histology and driver oncogenic alteration status[J]. Mod Pathol,2015,28(9):1154~1166.
[6] Song S G,J Lee J, Koh,et al. Utility of PD-L1 immunocytochemistry using body-fluid cell blocks in patients with non-small-cell lung cancer[J]. Diagn Cytopathol,2020,48(4):291~299.
[7] Tang Y W,Fang Y, Zhang,et al. The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs[J]. Oncotarget,2015,6(16):14209~14219.
[8] Reck MD, Rodriguez-Abreu A G, Robinson,et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell Lung cancer[J]. N Engl Med,2016,375(19):1823~1833.
[9] Rittmeyer A,F, Barlesi D,Waterkamp,et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK):a phase 3,open-label,multicentre randomised controlled trial[J]. Lancet,2017,389(10066):255~265.
[10] Pezzuto A F,Cappuzzo M, D'Arcangelo,et al. Prognostic value of p16 protein in patients with surgically treated non-small cell lung cancer; relationship with Ki-67 and PD-L1[J]. Anticancer Res,2020,40(2):983~990.
[11] Folescu R C M,Levai M L, Grigoras,et al. Expression and significance of Ki-67 in lung cancer[J]. Rom Morphol Embryol,2018,59(1):227~233.
[12] Sun J M ,W Zhou,Y L Choi,et al. Prognostic significance of PD-L1 in patients with non-small cell lung cancer:a large cohort study of surgically resected cases[J].Thorac Oncol,2016,11(7):1003~1011.
[13] Madore J,R E Vilain,A M Menzies,et al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients:implications for anti-PD-1/PD-L1 clinical trials[J]. Pigment Cell Melanoma Res,2015,28(3):245~253.